Solasia Pharma K.K. (TYO:4597)

Japan flag Japan · Delayed Price · Currency is JPY
31.00
-3.00 (-8.82%)
Mar 9, 2026, 3:30 PM JST
-13.89%
Market Cap 8.35B
Revenue (ttm) 429.00M
Net Income (ttm) -876.00M
Shares Out 269.26M
EPS (ttm) -3.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,134,400
Average Volume 29,769,305
Open 32.00
Previous Close 34.00
Day's Range 31.00 - 33.00
52-Week Range 27.00 - 48.00
Beta 1.17
RSI 58.31
Earnings Date Feb 13, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ... [Read more]

Sector Healthcare
Founded 2006
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4597
Full Company Profile

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial Statements

News

There is no news available yet.